Journal of the European Academy of Dermatology and Venereology最新文献

{"title":"Evidenced-based approach facilitates choosing between different topical compounds in acne vulgaris","authors":"Georgios Nikolakis, Christos C. Zouboulis","doi":"10.1111/jdv.20590","DOIUrl":"https://doi.org/10.1111/jdv.20590","url":null,"abstract":"<p>Acne vulgaris is the most common skin disease, and its pathogenesis has been the subject of extensive research over the last 3 to 4 decades. Its most important pathophysiologic pillars include a dysfunction in the keratinization of the follicular epithelium, which is tightly intertwined with an aberrant immunologic response, both innate and adaptive.<span><sup>1</sup></span> The interplay between epithelial cells and commensal bacteria such as <i>Cutibacterium acnes</i> leads to a proinflammatory microenvironment. Other factors, such as seborrhea, altered fatty acid composition and hormonal imbalance also contribute to the pathogenesis of this complex disease.<span><sup>2</sup></span></p><p>Several topical compounds have been developed and are effectively used for the treatment of mild-to-moderate acne, targeting one or more of the aforementioned factors. Retinoids exhibit both antiproliferative, comedolytic (keratolytic) and anti-inflammatory effects. Benzoyl peroxide (BPO) has bactericidal properties against <i>C. acnes</i> as well as mild comedolytic and anti-inflammatory properties. As for antibiotics, topical clindamycin is particularly effective against inflammatory acne lesions, but it can also affect biofilm and follicular microcomedone formation.<span><sup>3</sup></span> Erythromycin is also an effective alternative, but concerns have been raised regarding its potential to easily promote <i>C. acnes</i> resistance.</p><p>In a recent meta-analysis by Kakpovbia et al.<span><sup>4</sup></span> different topical treatments were compared by evaluating randomized control trials for topical treatments in acne with focus on efficacy. Publications based on absolute inflammatory and non-inflammatory lesion counts and the semiquantitative method of assessing treatment success based on the Investigator's Global assessment scale were included. Despite the dual targets of several compounds, the authors did not notice any significant differences among adapalene, azelaic acid, BPO, dapsone, erythromycin, clindamycin, salicylic acid, tretinoin and tazarotene.</p><p>Combination treatments with retinoid or topical antibiotic with BPO were the most effective among all treatments for inflammatory acne, while for non-inflammatory acne combination treatments with BPO and clindamycin did not outperform BPO<span><sup>4</sup></span>: The authors provide evidence supporting a differentiation of the therapeutic approach in patients according to their acne phenotype in order to achieve the maximal efficacy and contribute in avoiding unnecessary prescription of topical clindamycin for chronic skin disorders, which raises antibiotic resistance concerns.<span><sup>5</sup></span> The compound is ranked 125th most commonly prescribed medicine in the US and remains on the World Health Organization list of Essential Medicines, while its use is very often not limited to “in label” indications. Dermatologists frequently face constructive criticism concerning antibiotic st","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"39 4","pages":"711-712"},"PeriodicalIF":8.4,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.20590","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143690041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of providing clinical images and dermoscopy reports on the diagnosis of melanocytic skin lesions.","authors":"Belinda Lai, Hans Peter Soyer, Lin Zhu, Peter M Ferguson, Blake O'Brien, Tristan Dodds, Richard A Scolyer, Gerardo Ferrara, Katy J L Bell","doi":"10.1111/jdv.20655","DOIUrl":"https://doi.org/10.1111/jdv.20655","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143700736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antipsychotics in dermatology: Optimal choice of drugs for the treatment of delusional infestation and other potential uses for skin conditions","authors":"Katlein França","doi":"10.1111/jdv.20583","DOIUrl":"https://doi.org/10.1111/jdv.20583","url":null,"abstract":"<p>Delusional infestation (DI) is a psychiatric disorder defined by a fixed, false belief that one became infested by an organism without evidence to support this. Patients may report abnormal cutaneous sensations and present with excoriations, skin erosions, ulcerations and other skin lesions. In addition to a comprehensive history and detailed physical examination, laboratory workup should be considered depending on the clinical picture. DI can be categorized into primary or secondary. In primary DI, the patient has the delusion of being infested, but no other psychiatric or organic disorders are present. While the secondary forms of DI occur secondarily to other disorders such as psychiatric and organic diseases. Proper diagnostic workup for these patients is essential to rule out other explanations for symptoms and to investigate potential secondary causes of DI.<span>¹</span> Antipsychotic medications are the most common drugs used in the management of patients with primary DI.<span>²</span></p><p>Tang et al.<span>³</span> performed a multicentre, retrospective observational study with patients diagnosed with DI using anonymized electronic patient records from two hospitals in the United Kingdom. These authors found that amisulpride and risperidone were associated with a higher treatment response than other antipsychotics, such as quetiapine, aripiprazole and olanzapine. According to this study, amisulpride and risperidone should be considered the first-line treatment options for patients with DI. This important study provides insight into the optimal choice of antipsychotics for patients experiencing this challenging condition. The use of antipsychotic drugs for other dermatological conditions has been investigated in the past years. Gupta et al.<span>⁴</span> reviewed this topic and explained that these drugs can benefit dermatological patients due to their central nervous system and peripheral effects. They can be used as augmentation therapy of antidepressants, such as selective serotonin reuptake inhibitors (SSRI), for the management of trichotillomania (hair pulling disorder) and skin-picking disorder. Moreover, these drugs have a central postsynaptic dopamine D2 receptor-blocking effect with varying degrees of histamine H1 receptor, cholinergic muscarinic receptor and α1-adrenergic receptor-blocking effects, which could be potentially beneficial in the management of specific histamine or sympathetically mediated dermatological conditions. These drugs could have a potential role in treating other diseases, such as urticaria, pruritus and hyperhidrosis, but further research is warranted to confirm these benefits.</p><p>No conflict of interest with this paper content.</p>","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"39 4","pages":"717-718"},"PeriodicalIF":8.4,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.20583","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143690036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing biomarker-based prognostication in melanoma","authors":"Clio Dessinioti,&nbsp;Alexander J. Stratigos","doi":"10.1111/jdv.20591","DOIUrl":"https://doi.org/10.1111/jdv.20591","url":null,"abstract":"&lt;p&gt;Biomarker-driven risk stratification in cutaneous melanoma remains an area of intensive research, with the ultimate goal of refining prognostic accuracy and optimizing patient management. By identifying patients at higher risk for recurrence or melanoma-specific mortality, biomarkers have the potential to enhance patient counselling, tailor follow-up intensity and guide shared decision-making regarding adjuvant therapy.&lt;/p&gt;&lt;p&gt;In this issue, Dixon et al.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; propose the BAUSSS algorithm (Breslow thickness, Age, Ulceration, Subtype, Sex and Site) as a novel tool to estimate 15-year melanoma-specific mortality percentage (MSMP) in patients with primary melanoma. Their approach integrates a nomogram-derived table including Breslow thickness, age and ulceration (from the Lifemath online tool) and a second table incorporating the independent relative risks of melanoma subtype, sex and anatomical site (extracted from the El Sharouni study). The final MSMP estimate is derived by multiplying the respective values from both tables. However, several methodological considerations warrant attention. The El Sharouni study, which serves as a key data source for BAUSSS, was conducted in 5644 patients from the Melanoma Institute Australia (MIA), all of whom underwent sentinel lymph node biopsy (SLNB). That study's prognostic model included multiple variables—Breslow thickness, age, ulceration, subtype, sex, site, mitotic rate and regression—and was derived from a relatively short median follow-up period (3.9 years). The El Sharouni study analyzed melanoma-specific survival (MSS) only in the MIA cohort, and thus external validation was not possible, limiting the model's generalizability.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; Likewise, the development and validation of the new combined BAUSSS method to predict melanoma-specific mortality at 15 years was not described .&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;While prognostic models offer valuable insights, their clinical applicability should be interpreted with caution. External validation is crucial to ensure reproducibility across diverse patient populations, and model performance should be assessed using calibration plots and discrimination metrics (such as the concordance index or c-index). Current melanoma survival calculators vary in their predictions due to differences in included prognostic factors (e.g. categorical vs. continuous variables), statistical modelling approaches, patient cohorts used for model development. The AJCC online prediction tool, which was developed and validated for MSS for localized melanoma in US, Australian and European populations, focuses on thickness, ulceration, lesion site and age as key prognostic factors.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; The EORTC nomogram, designed for recurrence and melanoma-specific mortality in SLNB-negative patients, incorporates Breslow thickness, ulceration and primary site. Notably, external validation showed that adding sex, age, melanoma subtype and mito","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"39 4","pages":"719-720"},"PeriodicalIF":8.4,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.20591","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143690037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"On the importance of assessing stigma in dermatological research","authors":"Fanny C. Kpenou,&nbsp;Khaled Ezzedine","doi":"10.1111/jdv.20606","DOIUrl":"https://doi.org/10.1111/jdv.20606","url":null,"abstract":"&lt;p&gt;In this issue of the JEADV, an article by Butt et al.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; studied the psychometric properties of the revised internalized skin bias questionnaire. As the scientific literature accumulates evidence on the mental burden of skin diseases and the influence of psychological stress on their development, it has prompted a need for dermatological research to increasingly—and inevitably—consider complex psychosocial factors in order to further understand the hidden impact of these visible diseases. Indeed, in addition to being the largest organ, the skin is also the most exposed, and as such, any change in its appearance is likely to be visible. Thus, unlike many other conditions, skin diseases are often immediately noticeable, thereby impacting interactions with others and the environment. This inherent key effect makes the concept of stigma particularly relevant to skin diseases. In a recently published study,&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; we and others have invested efforts in developing a specific instrument aimed at assessing stigmatization across a relatively wide range of skin diseases in France. Within this context, it is important to recognize the intricacy of stigma. As a result, no single instrument can fully capture all relevant aspects of stigma, making it more challenging to assess this complex psychological construct.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; Furthermore, one should acknowledge that social circumstances and cultural differences pose an additional challenge to the dissemination of these types of instruments on a larger scale, among other barriers that researchers may face.&lt;/p&gt;&lt;p&gt;While integrating these critical processes in health studies is a difficult task, it naturally follows from the obligation to improve therapeutic strategies for (and with) patients according to a more holistic perspective. People with skin diseases were historically excluded from these efforts because common dermatoses were often neglected, but it is now well established that such disorders can lead to significant psychological and social impairments. The current conundrum highlights the necessity of adopting a more person-centred approach in therapeutic planning for skin diseases,&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; thus widening healthcare providers' perspectives to more than strictly medical interventions. The work of Butt et al. on internalized stigma, or self-stigma, is a needed step towards highlighting the importance of incorporating this critical yet underexplored dimension of stigmatization into everyday clinical practice. Although the authors have explored one of the many facets of stigmatization, there remains a need to explore other dimensions of this important concept, such as enacted stigma. These initiatives should be supported to continue delving into the complex relationships between psychosocial factors and skin diseases. This growing interest in integrating these layered psychological concepts into dermatological assessment will set a new g","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"39 4","pages":"721-722"},"PeriodicalIF":8.4,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.20606","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143690038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severe adverse drug reactions induced by lamotrigine: Are prescription guidelines being followed?","authors":"Alice Thorn, Bénédicte Lebrun Vignes, Anne Welfringer-Morin, Juliette Lebret, Brigitte Milpied, Paola Sanchez-Pena, Claire Bernier, Florence Tetart, Marie Tauber, Emilie Sbidian, Saskia Ingen-Housz-Oro","doi":"10.1111/jdv.20662","DOIUrl":"https://doi.org/10.1111/jdv.20662","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143710395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microsatellitosis of cutaneous melanomas in wide local excision specimens after excisional biopsy.","authors":"Pablo Vargas-Mora, Rubén González-Cuevas, Celia Requena, Esperanza Manrique-Silva, Víctor Traves, Eduardo Nagore","doi":"10.1111/jdv.20653","DOIUrl":"https://doi.org/10.1111/jdv.20653","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143692667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanoma.","authors":"Dirk Tomsitz, Elisabeth Livingstone, Carmen Loquai, Martin Kaatz, Ulrike Leiter, Bastian Schilling, Patrick Terheyden, Jessica Hassel, Michael Sachse, Jens Ulrich, Edgar Dippel, Frank Meiss, Claudia Pföhler, Alexander Kreuter, Rudolf Herbst, Michael Weichenthal, Lisa Zimmer, Friedegund Meier, Ricarda Rauschenberg, Peter Mohr, Fiona Brunnert, Imke von Wasielewski, Ralf Gutzmer, Dirk Schadendorf, Carola Berking, Selma Ugurel, Lucie Heinzerling","doi":"10.1111/jdv.20650","DOIUrl":"https://doi.org/10.1111/jdv.20650","url":null,"abstract":"<p><strong>Background: </strong>Adjuvant treatment with anti-PD1 antibodies has been shown to effectively reduce the risk of recurrence in patients with resected metastatic melanoma. Whether a full 12-month duration of treatment is needed to achieve full clinical benefit is not known. This study investigated the survival outcome depending on the duration of adjuvant anti-PD1 therapy.</p><p><strong>Methods: </strong>From the prospective multicentre real-world skin cancer registry ADOREG data of 620 patients who finished adjuvant treatment with nivolumab or pembrolizumab for AJCCv8 stage III/IV resected melanoma was analyzed. Recurrence-free survival (RFS) and overall survival (OS) were compared between patients with regular treatment duration (52 ± 4 weeks; n = 229) and no disease recurrence during therapy (A₁) and patients with a premature end of treatment (<48 weeks; n = 214, B). Patients with disease recurrence during adjuvant treatment were included in cohort A₂.</p><p><strong>Results: </strong>The median duration of follow-up was 26.0 months [interquartile range (IQR) 18.0-34.0] in group A₁ [median treatment duration 51.3 weeks (IQR 50.0-52.1) and 19.0 months (IQR 13.0-29.0)] in group B [median treatment duration 22.2 weeks (IQR 10.0-34.8)]. Reasons for early discontinuation were treatment-related side effects in 45.3% (n = 97) and other reasons than toxicity in 54.7% (n = 117). The 2-year rate of RFS was 72.4% (95% CI, 68.5-76.3) for patients in group B and 51.5% (95% CI, 48.8-54.2) in patients with regular and intended regular treatment duration (A₁ plus A₂). When analysing the patients who did not relapse during adjuvant treatment (A₁), there was a significantly higher RFS rate of 84.1% (95% CI, 81.5-86.7). When only assessing patients with a recurrence after more than 12 months after initiation of therapy, there was a trend towards better RFS in patients with regular treatment duration.</p><p><strong>Conclusion: </strong>In patients with resected metastatic melanoma, shorter treatment duration with anti-PD1 antibodies is not associated with a worse outcome.</p>","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143676888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-life effectiveness and safety of baricitinib in adults with alopecia areata: A multicentre study.","authors":"A Mourtada, C Douarec, M Wargny, V Hebert, Z Reguiai, P Joly, J Seneschal, C Toussaint, H Aubert, M Le Moigne, C Bernier, T Passeron, C Jacobzone Leveque, P Reygagne, S Le Naour, C Berthin, C Bara, M Fouchard, R Janela-Lapert, M Masson Regnault, M B Duval, M Jachiet, M Fenot, H Adamski, M E Marniquet, S Barbarot","doi":"10.1111/jdv.20657","DOIUrl":"https://doi.org/10.1111/jdv.20657","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143676856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pyemotes spp. dermatitis and comet sign.","authors":"Cesar Guijarro-Sanchez, Irene Rivera-Ruiz","doi":"10.1111/jdv.20648","DOIUrl":"https://doi.org/10.1111/jdv.20648","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143670210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}